Hongyu li | Breast Cancer | Best Researcher Award

Hongyu li | Breast Cancer | Best Researcher Award

Xinjiang medical university | China

AUTHOR PROFILE

SCOPUS

🎓EARLY ACADEMIC PURSUITS 

Assoc. Prof. Dr. Hongyu Li embarked on her academic journey at Xinjiang Medical University, where she earned her Doctor of Medicine degree and subsequently completed a Ph.D. in 2021. Her formative years were marked by rigorous academic training and an early interest in the oncology of breast diseases, which laid the foundation for her future specialization in breast cancer metastasis research.

👩‍🏢PROFESSIONAL ENDEAVORS 

Currently serving as an Associate Professor, Associate Chief Physician, and Doctor of Medicine at the Department of Breast Internal Medicine, Xinjiang Medical University Affiliated Tumor Hospital, Dr. Li brings over a decade of clinical expertise to the field. Her clinical focus is on the early detection, diagnosis, and management of breast cancer. She has been honored with prestigious awards including the “Tianchi Talent” Youth Doctor Award (2022), the Outstanding Postdoctoral Special Funding (2023), and was selected for the “789 Talent” Training Program (2024), cementing her reputation as a High-Level Talent and Outstanding Young Physician.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON BREAST CANCER 

Dr. Li’s scientific inquiry is anchored in understanding the molecular mechanisms of breast cancer metastasis, with a specific focus on breast cancer brain metastasis (BCBM)—a critical and poorly understood manifestation associated with poor prognosis. Her translational research bridges clinical challenges and bench-side investigations, aiming to identify novel biomarkers and potential therapeutic targets for BCBM.

She adopts an integrative approach that translates clinical observations into mechanistic questions, enhancing the effectiveness of future treatments and diagnostic strategies for late-stage breast cancer.

📚IMPACT AND INFLUENCE 

Dr. Li’s work is contributing to shaping the clinical paradigms in breast cancer care within the Xinjiang region and beyond. Her research is improving understanding of metastatic processes, especially in underrepresented ethnic populations. She is also involved in institutional collaborations and has served in editorial capacities, reinforcing her influence in both academic and clinical oncology spheres.

💪LEGACY AND FUTURE CONTRIBUTIONS 

Looking forward, Dr. Li aims to establish a dedicated translational research unit focused on metastatic breast cancer, particularly BCBM. She is committed to mentoring young researchers and expanding interdisciplinary collaborations that bridge molecular oncology with precision medicine. Her ultimate goal is to redefine treatment algorithms and enhance survival outcomes for patients with advanced-stage breast cancer.

🌍CONCLUSION 

Assoc. Prof. Dr. Hongyu Li stands as a beacon of translational oncology, seamlessly integrating clinical care with cutting-edge research. Her relentless pursuit of knowledge, commitment to public health, and strategic focus on a critically unmet need in oncology make her a deserving nominee for the Best Researcher Award.

 

📊🔬NOTABLE PUBLICATION:

Title: GRB2 promotes brain metastasis in HER2-positive breast cancer by regulating the Ras/MAPK pathway

Authors: Hongyu Li, Yalin Zhang, Xiao Han, Bingyu Li, Dan Liu, Gang Sun

Journal: Scientific Reports (Nature Publishing Group)

Year: 2025

Dr. Sadaf Haiyat | Hematolymphoid malignancy | Excellence in Research

Dr. Sadaf Haiyat | Hematolymphoid malignancy | Excellence in Research

MPMMCC, HBCH,Tata memorial centreVaranasi | India

AUTHOR PROFILE

GOOGLE SCHOLAR

🎓 EARLY ACADEMIC PURSUITS

Dr. Sadaf Haiyat laid a strong foundation for her medical career at Aligarh Muslim University (AMU), one of India’s premier institutions. She completed her MBBS in 2011 and pursued her MD in Pathology, graduating in 2016 with distinction. Her early education was marked by academic excellence, securing 75.5% in SSSC (10+2) with a distinction in Chemistry, and scoring a 99% merit in Science during high school at Nazareth Academy, Gaya.

🧑‍🏫 PROFESSIONAL ENDEAVORS

Dr. Haiyat has accrued over 11 years of rich experience in Anatomic and Clinical Pathology, including senior roles across reputed institutions such as J.N.M.C.H, AMU, Popular Multispeciality Hospital (Varanasi), Dr. Lal Path Labs (New Delhi), and currently serves as Assistant Professor and Consultant Oncopathologist at the Tata Memorial Centre/MPMMCC, Varanasi.

Her journey has spanned clinical diagnostics, academic teaching, lab administration, and quality assurance. She played a pivotal role in establishing a molecular pathology lab and actively leads EQAS audits and CAP/NABL compliance efforts.

🧪 CONTRIBUTIONS AND RESEARCH FOCUS ON HEMATOLYMPHOID MALIGNANCY

Dr. Haiyat has significantly contributed to the diagnosis and characterization of hematolymphoid malignancies, integrating morphological, immunohistochemical, molecular, and cytogenetic techniques. She has independently handled bone marrow biopsies, hematopathology diagnostics, and real-time PCR testing, including for EGFR, HER2/neu, and EWSR1 alterations. Her role in initiating molecular diagnostics for precision oncology marks a critical contribution to personalized medicine in resource-optimized settings.

📚 ACADEMIC CONTRIBUTIONS AND CITES

  • Total Publications: 25 (including 19 in international journals)

  • Presentations: 34 papers/posters at national and international platforms

  • Conferences Attended: 44 (10 international, 34 national)

  • Notable Thesis: “Role of Syndecan-1 (CD138) as a Diagnostic Biomarker for Plasma Cells in Patients of Abnormal Uterine Bleeding”

Her research is regularly cited in hematology and oncopathology contexts, particularly for rare case diagnostics and biomarker identification.

🌏 IMPACT AND INFLUENCE

Her academic and diagnostic influence extends internationally, evidenced by:

  • Membership in prestigious bodies such as the International Society of Gynecological Pathology, Association of Molecular Pathology (AMP), and the British Association of Urologic Pathology.

  • Awarded the 2024 Global Pathology Education Award by the College of American Pathologists (CAP) — a global recognition of excellence and commitment to medical education and diagnostics.

🏆 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Haiyat’s legacy is anchored in diagnostic precision, academic mentoring, and laboratory excellence. With a growing footprint in digital pathology, molecular diagnostics, and oncopathology, she is poised to lead next-generation pathology services, potentially extending to AI-assisted diagnostics, genomics-based therapeutic mapping, and international collaborations in cancer diagnostics.

She also mentors senior residents and scientific assistants, reflecting her commitment to nurturing the next wave of medical professionals.

🔚 CONCLUSION

Dr. Sadaf Haiyat stands out as a visionary pathologist, blending diagnostic expertise with academic vigor and clinical leadership. Her journey from a meritorious student to a recognized name in oncopathology reflects a commitment to excellence, education, and innovation. With a robust foundation, international accolades, and an eye toward the future of molecular and digital pathology, Dr. Haiyat is undeniably shaping the landscape of modern diagnostic medicine in India and beyond.

📊NOTABLE PUBLICATION:

Breast lymphomas: Clinical and pathological insights from a tertiary cancer care center in India
Journal: Indian Journal of Pathology and Microbiology
Year: 2024


Megaloblastic anemia: A common but often neglected cause of pyrexia of unknown origin
Journal: Journal of Translational Internal Medicine
Year: 2015


Epithelioid sarcoma: A diagnostic challenge of a rare presentation
Journal: Archives of International Surgery
Year: 2016


A Survey of Intestinal Lesions with Special Reference to Intestinal Tuberculosis in and Around Uttar Pradesh, India
Journal: International Journal of Current Microbiology and Applied Sciences
Year: 2015


Extradigital Glomus Tumour of Ankle in a Toddler: A Rare Case Report with Unusual Presentation
Journal: Journal of Medical and Surgical Pathology
Year: 2018

Dr. Wenhao Chen | Osteosarcoma | Best Researcher Award

Dr. Wenhao Chen | Osteosarcoma | Best Researcher Award

Zhejiang University School of Medicine Children’s Hospital National Clinical Research Center for Child Health | China

AUTHOR PROFILE

ORCID ID

SCOPUS

🎓 EARLY ACADEMIC PURSUITS

Dr. Wenhao Chen embarked on his medical journey at Peking University, where he completed his MD (2004–2012), laying a strong foundation in clinical and surgical sciences. His early exposure to academic rigor and translational research in one of China’s most prestigious institutions catalyzed his long-term interest in orthopedics and musculoskeletal oncology.

🏆 PROFESSIONAL ENDEAVORS

Currently serving as the Head of the Department of Orthopedics at the Children’s Hospital, Zhejiang University School of Medicine, Dr. Chen leads both clinical operations and scientific innovation. He completed his postdoctoral fellowship (2019–2020) at Massachusetts General Hospital (MGH), USA, a globally renowned center, where he honed his skills in translational and molecular orthopedics.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON OSTEOSARCOMA

Dr. Chen’s core research focus centers on osteosarcoma, Ewing sarcoma, and bone regeneration mechanisms. His work spans from genomic risk modeling to machine learning applications in prognosis prediction. Notably:

  • Identification of LARS as an essential gene in osteosarcoma proliferation via CRISPR-Cas9 screens (J Transl Med, 2022).

  • Developed prognostic nomograms and glycolysis-based risk scores to stratify osteosarcoma survival (J Orthop Res, 2022; Medicine, 2019).

  • Investigated radiotherapy sensitivity and metastatic prediction in osteosarcoma (J Cancer Res Clin Oncol, 2023).

His integration of molecular biology, AI modeling, and clinical data science reflects a translational approach that bridges lab discoveries with bedside applications.

🌍 IMPACT AND INFLUENCE

Dr. Chen’s body of work demonstrates multidisciplinary impact:

  • Oncology (osteosarcoma, Ewing sarcoma)

  • Orthopedic surgery innovations

  • Inhalation therapy for pulmonary fibrosis (J Transl Med, 2024)

  • Neural regeneration using viral gene therapy (Brain Res Bull, 2017)

His collaborations with top U.S. institutions and international teams exemplify his global research footprint and scientific leadership.

📖 ACADEMIC CITATIONS AND RECOGNITION

With 17 peer-reviewed publications, many in high-impact journals such as FASEB Journal, Journal of Translational Medicine, and Journal of Orthopaedic Research, Dr. Chen has amassed significant citations in the fields of oncology, orthopedics, and translational medicine, reflecting the clinical utility and scientific merit of his contributions.

🔮 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Chen’s vision for the future includes:

  • Developing non-invasive diagnostic models for early osteosarcoma detection

  • Expanding research into bone-tissue engineering and regeneration

  • Training future orthopedic surgeons and clinician-scientists with dual clinical and computational expertise

🌍CONCLUSION 

Dr. Wenhao Chen stands at the forefront of orthopedic science, blending clinical acumen, molecular insights, and computational power to reshape musculoskeletal disease treatment.

 

📊🔬NOTABLE PUBLICATION:

Title: The phosphatase CTDSPL2 promotes proliferation, invasion, metastasis and regorafenib resistance in osteosarcoma
Journal: Journal of Bone Oncology
Year: 2025

Title: Diminished GALNS activity in induced pluripotent stem cells of mucopolysaccharidosis IVA caused by compound p.S162Y and p.C165F mutation
Journal: QJM: An International Journal of Medicine
Year: 2025

Title: Chaperone‐mediated autophagy protects the bone formation from excessive inflammation through PI3K/AKT/GSK3β/β‐catenin pathway
Journal: The FASEB Journal
Year: 2024

Title: Outcomes of two-stage double-level rotational osteotomy in treating patients with congenital proximal radioulnar synostosis
Journal: World Journal of Pediatric Surgery
Year: 2023

Title: A novel risk score model based on glycolysis‐related genes and a prognostic model for predicting overall survival of osteosarcoma patients
Journal: Journal of Orthopaedic Research
Year: 2022

Zu-Chian Chiang | Biomedicine | Best Researcher Award

Dr. Zu-Chian Chiang | Biomedicine | Best Researcher Award

Fujian Normal University | China

Author Profile

Scopus

🔬 Dr. Zu-Chian Chiang, Ph.D.

Postdoctoral Fellow | Biomedical Research & Targeted Cancer Therapy Specialist 🧪🧬🎯
Fujian Normal University, Biomedical Research Center of Southern China

Dr. Zu-Chian Chiang is a distinguished Postdoctoral Fellow at the Biomedical Research Center of Southern China, Fujian Normal University, Qishan Campus, in Fuzhou, China. With a strong foundation in Materials and Chemical Engineering (Ph.D., National United University, Taiwan) and Chemistry (M.S., Tunghai University, Taiwan), Dr. Chiang has dedicated his academic journey to the intersection of materials science, chemistry, and biomedical innovation.

His research interests span a broad range of cutting-edge biomedical fields, including:
🔹 Functional peptide synthesis for cancer and bone tissue applications
🔹 Development of biomicro/macro-molecular complexes for regenerative medicine
🔹 Design of Antibody Drug Conjugates (ADCs) for targeted cancer therapy
🔹 Engineering of aptamers as blockers, agonists, or antagonists in cancer treatment

💡 Dr. Chiang has also contributed to academia through teaching roles, serving as a Teaching Assistant in Organic Chemistry and Chemical Engineering Thermodynamics at National United University.

🏆 Awards & Honors

  • 2020: Science and Technology Commissioner, Quanzhou, Fujian Province

  • 2017: Chairman Award, Miaoli Southeast Rotary Club, Rotary International Taiwan

  • 2016: Biotech Elite Training Reserve Program Awardee, National Taiwan University, Ministry of Science and Technology

🌐 Professional Affiliations & Contributions

  • Peer Reviewer, International Journal of Biological Macromolecules

  • Chief Club President (CP), Miaoli Xindong Satellite Rotary Club, Rotary International District 3501

  • Committee Member, Chinese Rotary Education Foundation (West District Chapter)

  • Member, Taiwan Biochemical Society 🧬

  • Member, Chinese Chemical Society ⚗️

  • Member, Chinese Society of Cell Biology 🔬

Dr. Chiang continues to blend his expertise in chemistry and biomedical engineering to push forward translational research, particularly in the field of cancer therapeutics and regenerative biomaterials.

🛡️ Conclusion

Dr. Zu-Chian Chiang stands at the forefront of interdisciplinary biomedical research, merging materials science, chemistry, and biotechnology to pioneer novel solutions in cancer therapy and regenerative medicine. His dedication to scientific advancement, combined with his active involvement in academic, professional, and community networks, highlights his role as a passionate innovator and collaborative leader in the global biomedical field. With a strong track record and a clear vision, Dr. Chiang continues to make impactful contributions that bridge the gap between cutting-edge research and clinical application. 🌍🔬💡

📊🔬NOTABLE PUBLICATION:

1. Development of Novel CD47-Specific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer In Vitro and In Vivo

Authors: Zu-Chian Chiang*, Shan Xu, Xiangqian Zhao, Min Liu*, Jizhen Lin*, Qi Chen*
Journal: Frontiers in Oncology
Year: 2022

2. Generation and Characterization of 7DC-DM1: A Non-Cleavable CD47-Targeting Antibody–Drug Conjugate with Antitumor Effects

Authors: Zu-Chian Chiang*, Shubin Fang, Yangkun Shen, Jizhen Lin, Qi Chen
Journal: International Journal of Biological Macromolecules
Year: 2025

3. Strengthening Effect of Thalidomide Combined with Anti-PD1 Antibody on Enhancing Immunity for Lung Cancer Therapy

Authors: Qing Liu, Zu-Chian Chiang#, Xiangxian Zhao, Dong-Ya Cui, Xinxin Li, Hao Chen, Fangyu Lin, Tao Jiang, Qi Chen, Xiaoyan Lin*
Journal: Current Pharmaceutical Biotechnology
Year: 2024

4. Preparation and Characterization of Antibody–Drug Conjugates Acting on HER2-Positive Cancer Cells

Authors: Zu-Chian Chiang, Yi-Kai Chiu, Cheng-Chung Lee, Yueh-Liang Tsou, Hong-Sen Chen, Horng-Ru Hsu, Tzung-Jie Yang
Journal: PLOS ONE
Year: 2020

Yingxue Jin | Pharmaco-Oncology | Excellence in Oncology Research Award

Prof. Dr. Yingxue Jin | Pharmaco-Oncology | Excellence in Oncology Research Award

Harbin Normal University | China

AUTHOR PROFILE

Scopus

🧑‍🏫 YINGXUE JIN – PROFESSIONAL PROFILE

🎓 EARLY ACADEMIC PURSUITS

Yingxue Jin embarked on his academic journey with a strong foundation in science, eventually earning a Doctor of Science degree from Pusan National University in Korea in 2003. His academic background laid the groundwork for his expertise in pharmaceutical engineering and drug design. During his doctoral studies, he specialized in small molecule cyclic peptide drugs and nanodrug delivery systems, establishing a solid base for his future research contributions.

💼 PROFESSIONAL ENDEAVORS

Yingxue Jin has accumulated over three decades of experience in academia and research, holding key positions in prestigious institutions and companies:

  • Professor at Jiamusi University (1990 – 1999): Contributed to teaching and research in pharmaceutical sciences.

  • Senior Researcher at Korea Ilshin Chemical Company (2003 – 2004): Engaged in advanced chemical research, expanding his expertise in molecular synthesis.

  • Postdoctoral Researcher at Taiwan University, China (2005 – 2006): Conducted postdoctoral studies, refining his knowledge in pharmaceutical engineering and drug delivery mechanisms.

  • Professor at Harbin Normal University, China (2006 – Present):

    • Serving as Head of the Department of Pharmaceutical Engineering.

    • Director of Heilongjiang Chemical Society of China, promoting chemical science advancements.

    • Awarded the honorary title of “Famous Teacher” at Harbin Normal University, recognizing his excellence in education and mentorship.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON PHARMACO-ONCOLOGY

Yingxue Jin’s primary research interests revolve around:

  • Design and Synthesis of Small Molecule Cyclic Peptide Drugs: Developing novel peptide-based therapeutic agents for various diseases, including cancer.

  • Anti-Tumor Nanodrug Delivery Systems: Innovating targeted drug delivery methods to enhance the efficacy and precision of cancer treatments.

  • Project Leadership:

    • Presided over two projects funded by the Natural Science Foundation of China (NSFC).

    • Led the implementation of one key project and two general projects under the Natural Science Foundation of Heilongjiang Province, China.

    • Supervised three natural science projects for the Heilongjiang Provincial Education Department, China.

🏅 IMPACT AND INFLUENCE

Yingxue Jin’s impactful contributions have been widely recognized through multiple awards and honors:

  • Natural Science and Technology Award of Heilongjiang Province: Acknowledging his significant scientific achievements.

  • Science and Technology Award of Heilongjiang Provincial Education Department: Recognizing his contributions to technological advancements in education.

  • Teaching Quality Award at Harbin Normal University (Multiple Occasions): Honoring his dedication to educational excellence and mentorship.

📚 ACADEMIC CITATIONS

Throughout his career, Yingxue Jin’s research has been widely cited in scientific publications, reflecting the influence and relevance of his work in the fields of pharmaceutical sciences, chemical engineering, and nanomedicine. His contributions have been referenced in numerous peer-reviewed journals, further establishing his reputation as a leading researcher in his field.

🌍 LEGACY AND FUTURE CONTRIBUTIONS

Yingxue Jin’s legacy is marked by his dedication to scientific innovation, educational mentorship, and pharmaceutical advancements. Moving forward, he aims to:

  • Expand his research in nanodrug delivery systems, focusing on precision medicine for oncology applications.

  • Foster collaborations with international research institutions to drive cross-disciplinary advancements.

  • Continue mentoring the next generation of scientists, contributing to the development of future leaders in pharmaceutical sciences.

🛡️ KEY ACHIEVEMENTS AND RECOGNITION

  • Honorary Title: Famous Teacher of Harbin Normal University.

  • Leadership Roles: Head of the Department of Pharmaceutical Engineering and Director of Heilongjiang Chemical Society of China.

  • Award-Winning Scientist: Recipient of multiple science and technology awards.

  • Renowned Educator: Consistently recognized for outstanding teaching quality.

🚀 CONCLUSION

Yingxue Jin’s extensive experience, innovative research, and dedication to scientific excellence and education have positioned him as a distinguished figure in the field of pharmaceutical sciences. His continued contributions to nanodrug delivery systems and cyclic peptide drug design are paving the way for groundbreaking advancements in cancer treatment and precision medicine.

 

📊🔬NOTABLE PUBLICATION:
  • 1️⃣ Exploring the Potential of Cyclic Peptidyl Antitumor Agents Derived from Natural Macrocyclic Peptide Phakellistatin 13

    Authors: Tong T. Li, Shitian S. Jiang, Tingting T. Li, Yingxue Y. Jin, Zhiqiang Z. Wang
    Journal: Journal of Medicinal Chemistry
    Year: 2024


    2️⃣ Enhanced Catalytic Activity of Fe3O4-Carbon Dots Complex in the Fenton Reaction for Enhanced Immunotherapeutic and Oxygenation Effects

    Authors: Guanghao G. Li, Yujun Y. Bao, Hui H. Zhang, Zhiqiang Z. Wang, Yingxue Y. Jin
    Journal: Journal of Colloid and Interface Science
    Year: 2024


    3️⃣ A Novel Nanomedicine Integrating Ferroptosis and Photothermal Therapy, Well-Suitable for PD-L1-Mediated Immune Checkpoint Blockade

    Authors: Yujun Y. Bao, Guanghao G. Li, Siqi S. Li, Changhong C. Guo, Yingxue Y. Jin
    Journal: Materials Today Bio
    Year: 2024


    4️⃣ Targeted Delivery of Rhein via Hyaluronic Acid Modified Liposomes for Suppression of Growth and Metastasis of Breast Cancer

    Authors: Jingchun J. Wang, Dijing D. Fan, Defu D. Cai, Yingxue Y. Jin
    Journal: International Journal of Biological Macromolecules
    Year: 2024


    5️⃣ DFT-Aided Stereo-Structural and Electronic Structure Studies of Poly-Hydroxyl Substituted Chlorophyllous Molecules

    Authors: Xiong X. Zhang, Tingting T. Li, Qi Q. Wang, Wen W. Fang, Zhiqiang Z. Wang
    Journal: Computational and Theoretical Chemistry
    Year: 2024

Assoc Prof Dr. Chen Wang | Anti-tumor Nanomaterials | Best Researcher Award

Assoc Prof Dr. Chen Wang | Anti-tumor Nanomaterials | Best Researcher Award

Guangxi Medical University Cancer Hospital | China

Author Profile

Scopus

Orcid id

🌟 Distinguished Scientist Award: Dr. Chen Wang 🌟

Full Name: Chen Wang
Gender: Male
Designation: Associate Research Fellow
Department: Guangxi Key Laboratory of Basic and Translational Research for Colorectal Cancer
Institution/Organization: Guangxi Medical University Cancer Hospital
Qualification: Ph.D.
Area of Specialization: Oncology Therapeutics and Novel Approaches
Sub Division: Anti-tumor Nanomaterials

📚 Education and Experience

Born in Liaoning, China, in 1988, Dr. Chen Wang has dedicated his career to advancing cancer treatment through innovative research in materials science and engineering. He earned his BS (2010) and MS (2013) degrees from Shenyang University of Technology, followed by a Ph.D. from Harbin Engineering University in 2019. Dr. Wang’s postdoctoral research took place at the Changchun Institute of Applied Chemistry and Southern Medical University. He began his academic career at Jilin University of Chemical Technology and joined Guangxi Medical University Cancer Hospital in 2020, becoming an associate research fellow in 2022.

🧬 Research and Innovations

Dr. Wang specializes in the synthesis and clinical application of novel anti-tumor nanomaterials. His pioneering work on calcium overload as a novel treatment for tumor cells has garnered significant attention. The development of GMCP (GOx@MMPB@CaP-PEG) nanoparticles showcases his innovative approach, combining enhanced intratumor reactive oxygen species (ROS) levels with photothermal therapy to promote apoptosis in tumor cells.

🏆 Achievements

  • Publications: Nearly 30 SCI-indexed original articles, including 11 as first/corresponding author.
  • Projects: Completed 12 research projects, with 5 as the principal investigator.
  • Patents: Holds 7 patents.
  • Editorial Roles: Serves on the editorial boards and as a reviewer for multiple journals.
  • Memberships: Member of the China Food and Drug Enterprise Quality and Safety Promotion Association.
  • Citations: 495 citations in Scopus/Web of Science.
  • H-index: 13.
  • Impact Factor: Cumulative impact factor of 141.8 over the last three years.

Dr. Wang’s work in oncology therapeutics, particularly in anti-tumor nanomaterials, positions him as a leading figure in his field, making him a deserving recipient of the Distinguished Scientist Award.

🌐 Professional Links

📄 Certifications

  • Education Proof (Ph.D.): 1021722019110003
  • Government ID (Passport): E36369406

Dr. Chen Wang’s dedication to research, innovation, and the application of novel cancer treatments underscores his significant contributions to the field of oncology therapeutics.

 

📊🔬Notable Publication:

 

 

 

 

Prof Dr. Rommel MarioRodriguez Burbano – Oncology and Precision Medicine – Best Researcher Award

Prof Dr. Rommel MarioRodriguez Burbano - Oncology and Precision Medicine - Best Researcher Award

Ophir Loyola Hospital - Brazil

AUTHOR PROFILE

Google Scholar

Scopus

Orcid

EARLY ACADEMIC PURSUITS

Rommel Mario Rodríguez Burbano began his academic journey by earning a degree in Biomedicine from the Federal University of Pará in 1989. He then pursued further education, completing his Master's (1993) and Ph.D. (1998) in Biological Sciences (Genetics) from the Faculty of Medicine of Ribeirão Preto, University of São Paulo.

PROFESSIONAL ENDEAVORS

After completing his formal education, Rommel embarked on a diverse and impactful professional career. He conducted post-doctoral research in Morphology at the Discipline of Genetics, Escola Paulista de Medicina, Federal University of São Paulo in 2005. Currently, he holds the prestigious position of Full Professor at the Federal University of Pará.

CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY AND PRECISION MEDICINE

Rommel Mario Rodríguez Burbano's contributions to academia are significant and multifaceted. His research primarily focuses on Human Genetics, Cell Biology, and Oncology. Throughout his career, he has demonstrated a keen interest in understanding molecular mechanisms underlying diseases, particularly cancer.

IMPACT AND INFLUENCE

Rommel's work has had a profound impact on the scientific community. His extensive publication record, comprising 296 scientific articles in specialized journals, one book, and seven book chapters, reflects his dedication to advancing knowledge in his field.

ACADEMIC CITATIONS

Rommel's research output has garnered considerable attention, as evidenced by his numerous academic citations. His work is widely recognized and cited by peers, contributing significantly to the advancement of scientific knowledge.

LEGACY AND FUTURE CONTRIBUTIONS

As a mentor and supervisor, Rommel has played a pivotal role in shaping the next generation of scientists. He has supervised a total of 44 master's theses, 41 doctoral theses, and mentored five postdoctoral fellows. His legacy extends beyond his own research contributions, influencing the work of numerous scholars who have benefited from his guidance and expertise.

HIGHLIGHTS

Rommel currently serves as the Coordinator of the Molecular Biology Laboratory at Hospital Ophir Loyola in Belém, Pará, indicating his leadership in translational research.He holds the Process and Molecular Biomarker patent, demonstrating his innovative approach to addressing scientific challenges.Rommel's involvement in editorial boards of 12 scientific journals and his role as a reviewer for numerous scientific publications underscore his commitment to peer-reviewed research and quality scholarship.

NOTABLE PUBLICATIONS

Homocystein, Vitamin B12 and Folic Acid as Screening Biomarkers in Early Diagnosis and Gastric Cancer Monitoring.  2024

Efficacy and Safety of Anti-CD38 Monoclonal Antibodies in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Randomized Clinical Trials. 2024

Molecular Profile of Variants Potentially Associated with Severe Forms of COVID-19 in Amazonian Indigenous Populations. 2024 (1)

Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials. 2024

PARP1 Characterization as a Potential Biomarker for BCR::ABL1 p190+ Acute Lymphoblastic Leukemia. 2023

 

 

Dr. Takashi Takeshita – Cancer Genetics – Best Researcher Award

Dr. Takashi Takeshita - Cancer Genetics - Best Researcher Award

Kumamoto City Hospital - Japan

Author Profile

Google Scholar

Scopus

Orcid

EARLY ACADEMIC PURSUITS

Takashi Takeshita initiated his academic journey by obtaining a Medical Doctorate (M.D.) from the National Defense Medical College, Saitama, Japan, in 2005. He furthered his education by earning a Ph.D. from St. Marianna University School of Medicine, Kanagawa, Japan, in 2012. These early academic pursuits established the foundation for his future contributions to cancer genetics.

PROFESSIONAL ENDEAVORS

Since 2022, Takashi Takeshita has been serving as the Chief of Breast and Endocrine Surgery at Kumamoto City Hospital, Japan. His professional journey is marked by significant achievements, including the receipt of several prestigious awards: the 2017 Research Award from the Japanese Breast Cancer Society, the 2017 Research Award from the Japanese Society of Medical Oncology, the 2018 Young Investigator’s Award from the Japan Surgical Society, and the 2018 Excellent Presentation Award from the Japanese Breast Cancer Society.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER GENETICS 

Takashi Takeshita's 19-year research career spans various research institutes, showcasing a robust expertise in cancer genetics. His focus includes genetic analysis of clinical specimens, utilizing techniques such as digital PCR for tumor tissue and plasma DNA, immunohistochemical staining, automated assay robot operation, and more. His experience in large-scale cell culture and comprehensive knowledge of molecular biology, pharmacology, and analytical methods underscore his dedication to advancing cancer research.

IMPACT AND INFLUENCE

The awards received by Takashi Takeshita, coupled with his role as the Chief of Breast and Endocrine Surgery, affirm his impact and influence in the medical field. His leadership and contributions to cancer genetics, particularly in breast cancer research, position him as a prominent figure. His membership in esteemed academic societies, including the Japanese Breast Cancer Society, Japan Surgical Society, Japanese Cancer Association, Japanese Society of Medical Oncology, and the American Association for Cancer Research, further reflects his influence on a global scale.

ACADEMIC CITES

Takashi Takeshita's involvement in renowned academic societies and receipt of research awards suggest that his work likely receives recognition and citations within the scientific community. His expertise in genetic analysis and clinical research contributes to the advancement of cancer genetics literature.

LEGACY AND FUTURE CONTRIBUTIONS HIGHLIGHT

Takashi Takeshita's legacy is built upon a foundation of excellence in cancer genetics, marked by numerous awards and leadership roles. His dedication to advancing breast and endocrine surgery and his contributions to genetic analysis techniques set the stage for a lasting impact. Looking ahead, Takeshita is poised to continue making significant contributions to cancer genetics, shaping the future landscape of research in breast cancer and beyond. His membership in international societies signifies a commitment to global collaboration and further advancements in cancer research.

NOTABLE PUBLICATIONS

Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing. 2024

Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment. 2023

Development of a Machine Learning-Based Prognostic Model for Hormone Receptor-Positive Breast Cancer. 2023 (5)

Fulvestrant plus palbociclib in advanced or metastatic hormone. 2023 (2)

High dose of dexamethasone attenuates docetaxel-induced fluid retention in breast cancer treatment. 2023

Prof Dr.Sheeren Mohammed Khaled – Cancer Science – Best Researcher Award

Prof Dr.Sheeren Mohammed Khaled - Cancer Science - Best Researcher Award

King Abdullah Medical City - Saudi Arabia

AUTHOR PROFILE

Scopus

Orcid

EARLY ACADEMIC PURSUITS:

Dr. Sheeren Mohammed Khaled began her academic journey with a Bachelor of Medicine and Surgery (M.B., B.Ch.) from Benha University, Faculty of Medicine, graduating with excellence in December 2005. Following this, she pursued her Master's degree in Cardiology at Benha University, graduating with a very good grade in September 2010. Dr. Khaled continued her academic endeavors, earning her MD degree in Cardiology from Benha University in May 2014.

PROFESSIONAL ENDEAVORS:

Dr. Khaled's professional journey reflects a rich and diverse experience in the field of Cardiology: Consultant Cardiology at King Abdullah Medical City (KAMC), Associate Professor of Cardiology at Benha University, Lecturer of Cardiology at Benha University Hospital, Associate Consultant Cardiology at KAMC, Cardiology Specialist at Alzahra Hospital (Saudi Arabia), Assistant Lecturer at Benha University Hospital.

IMPACT AND INFLUENCE ON CANCER SCIENCE

Dr. Sheeren Mohammed Khaled has made significant contributions to the field of cancer science through her roles as a clinician, educator, and researcher. Her commitment to teaching, clinical excellence, and research activities has had a positive impact on both students and colleagues.

ACADEMIC CITATIONS:

Dr. Khaled's academic citations are reflective of her contributions to research studies, the supervision of theses, and active involvement in various scientific committees.

LEGACY AND FUTURE CONTRIBUTIONS:

Dr. Sheeren Mohammed Khaled's legacy lies in her dedication to advancing cardiology education, patient care, and research. Her future contributions are anticipated to further enrich the field through continued excellence in teaching, clinical practice, and impactful research initiatives.

NOTABLE PUBLICATIONS

Myocardial recovery after percutaneous coronary intervention in coronary artery disease patients with impaired systolic function- predictive utility of global longitudinal strain.2022

Severe Left Ventricular Dysfunction Earlier after Acute Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention: Predictors and In-Hospital Outcome– A Middle Eastern Tertiary Center Experience.2023

Cardiogenic Shock Among Patients with Acute ST-Segment Elevation Myocardial Infarction in a Middle Eastern Country: A Single-Center Experience.2023

 

Personalized Cancer Treatment

Introduction: Personalized cancer treatment represents a paradigm shift in oncology, moving away from one-size-fits-all approaches and towards tailoring treatments based on an individual’s unique genetic, molecular, and clinical characteristics. This approach holds the promise of maximizing treatment efficacy while minimizing side effects, offering new hope for cancer patients.

Subtopics in Personalized Cancer Treatment:

Genomic Profiling: Genomic analysis of a patient’s tumor can identify specific genetic mutations and alterations that drive cancer growth. Targeted therapies are then designed to attack these specific molecular vulnerabilities, leading to more effective treatment.

Immunotherapy and Immune Profiling: Personalized cancer treatment extends to immunotherapy, where the patient’s immune system is harnessed to fight cancer. Immune profiling helps identify immune checkpoints and tumor-specific antigens, aiding in the selection of suitable immunotherapies.

Biomarker-Based Therapy: Biomarkers such as hormone receptors, HER2 status, and PD-L1 expression guide treatment decisions in breast, lung, and other cancers. Personalization ensures that patients receive therapies tailored to their tumor’s unique characteristics.

Treatment Resistance Mitigation: Personalized approaches are essential in combating treatment resistance. Continuous monitoring and adaptation of treatment regimens based on evolving tumor profiles can help overcome resistance and extend the duration of response.

Clinical Trial Matching: Personalized treatment extends to the realm of clinical trials, where patients are matched with experimental therapies that align with their tumor’s genetic makeup. This accelerates drug development and provides patients with access to cutting-edge treatments.

These subtopics highlight the transformative potential of personalized cancer treatment, emphasizing its role in optimizing patient outcomes, minimizing adverse effects, and advancing the field of oncology towards precision medicine.